The legally binding text is the original French version
19 jan 2011 ABUFENE was prescribed mainly for menopausal and perimenopausal disorders (85.7%). 6. TRANSPARENCY COMMITTEE CONCLUSIONS. 6.1. Actual benefit.
ABUFENE - CT - 7419
6 pri 2011 ABUFENE n'a pas de place dans la stratégie thérapeutique des ... ABUFENE 400 mg et bouffées de chaleur. Etude en double aveugle versus ...
ABUFENE 400 mg RI
ABUFENE 400 mg comprimés - Boîte de 30 comprimés – Code CIP : 335 289 2. Laboratoire BOUCHARA RECORDATI SAS. Bêta-alanine. Date d'AMM : 23 septembre 1991.
Fiche Avis nouveau médicament
6 pri 2011 ABUFENE est utilisé dans les bouffées de chaleur de la ménopause. Les données disponibles ne permettant pas de le distinguer d'un placebo ...
NOTICE
2 tet 2012 QU'EST-CE QUE ABUFENE 400 mg comprimé ET DANS QUELS CAS EST-IL UTILISE ? 2. QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE ABUFENE ...
Notice 64728712
20 sht 2017 Qu'est-ce que ABUFENE 400 mg comprimé et dans quels cas est-il utilisé ? 2. Quelles sont les informations à connaître avant de prendre ...
Mis à jour le : 17/04/2015 Dénomination du médicament ABUFENE
17 pri 2015 Ne prenez jamais ABUFENE 400 mg comprimé : · si vous êtes allergique (hypersensible) à la substance active ou à l'un des autres composants ...
NOTICE
3 maj 2013 QU'ESTCE QUE ABUFENE 400 mg comprimé ET DANS QUELS CAS ESTIL UTILISE ? 2. QUELLES SONT LES INFORMATIONS A CONNAITRE AVANT DE PRENDRE ABUFENE ...
Women dealing with hot flushes: the role of β-alanine
This review will discuss the current pharma- cological management of HF and will present the role of β-alanine (Abufène/Klimalanin Labora- toires Bouchara-
Fletorja Zyrtare Viti 2018 – Numri 103
3 korr 2018 ABUFENE. Tableta 400 mg. BETA-ALANINE. Kuti me 30. 4. ACC 200. Pluhur për tretësirë për përdorim nga goja 200 mg/qeskë. ACETYLCYSTEINE. Kuti me ...
ABUFENE - CT - 7419
6 avr. 2011 ABUFENE 400 mg comprimé. B/1 plaquette thermoformée aluminium PVC de 30 comprimés (CIP : 335 289-2). Laboratoires BOUCHARA - RECORDATI.
ABUFENE 400 mg RI
ABUFENE 400 mg comprimés - Boîte de 30 comprimés – Code CIP : 335 289 2. Laboratoire BOUCHARA RECORDATI SAS. Bêta-alanine. Date d'AMM : 23 septembre 1991.
Fiche Avis nouveau médicament
6 avr. 2011 ABUFENE n'a pas de place dans la stratégie thérapeutique des bouffées de chaleur. Données cliniques. La seule étude versus placebo publiée ...
The legally binding text is the original French version
19 janv. 2011 ABUFENE 400 mg tablets. B/30 (CIP code: 335 289-2). Applicant: BOUCHARA RECORDATI. Beta-alanine. ATC code: G03X.
ANSM - Mis à jour le : 17/04/2015 Dénomination du médicament
17 avr. 2015 ABUFENE 400 mg comprimé. Bêta-alanine. Encadré. Veuillez lire attentivement cette notice avant de prendre ce médicament car elle contient ...
Dénomination du médicament ABUFENE 400 mg comprimé Bêta
ABUFENE 400 mg comprimé. Bêta-alanine. Encadré. Veuillez lire attentivement cette notice avant de prendre ce médicament car elle contient des.
ABUFENE 400 mg comprimé Bêtaalanine
ABUFENE 400 mg comprimé. Bêtaalanine. Veuillez lire attentivement cette notice avant de prendre ce médicament car elle contient des informations
AbuFène
Liste des excipients à effet notoire : amidon de blé (gluten). 3. coilmEilT PRENDRE ABUFÈNE. 4oo mg comprimé ? Pqrqlogie. Se conformer strictement
Les traitements non estrogéniques des symptômes de la
Abufène 400 mg et bouffées de chaleur. Etude en double aveugle versus placebo. La revue du praticien – Medecine generale 1991 ; 5 : 2 385-2 388.
Fiche Recommandation de Bonne Pratique Hormonothérapie
Homéopathie grain de pollen
TRANSPARENCY COMMITTEE
OPINION
19 January 2011
ABUFENE 400 mg, tablets
B/30 (CIP code: 335 289-2)
Applicant: BOUCHARA RECORDATI
Beta-alanine
ATC code: G03X
Date of Marketing Authorisation: 23 September 1991 (national procedure)Reason for request
: Renewal of inclusion on the list of medicines refundable by NationalHealth Insurance.
Medical, Economic and Public Health Assessment Division 2/51. CHARACTERISTICS OF THE MEDICINAL PRODUCT
1.1. Active ingredient
Beta-alanine
1.2. Indication
"For use in menopausal hot flushes."1.3. Dosage
"The dosage is 1 to 2 tablets a day. This dosage can safely be increased to 3 tablets a day if necessary. The medicinal product is to be administered for periods of 5 to 10 days until the hot flushes abate. When they reappear, a further cycle of drug treatment must be administered again for the same period. As no habituation is observed, treatment can be prolonged throughout the entire duration of clinical vasomotor disorders, with no time limit."2. SIMILAR MEDICINAL PRODUCTS
2.1. ATC Classification (2010)
G : Genitourinary system and sex hormones
G03 : Sex hormones and modulators of the genital system G03X : Other sex hormones and modulators of the genital system2.2. Medicines in the same pharmaco-therapeutic category
2.2.1 Strictly comparator medicines
Not applicable.
2.2.2 Not-strictly-comparator medicines
Not applicable.
2.3. Medicines with a similar therapeutic aim
Hormone replacement treatments for the menopause
3/53. REMINDER OF THE COMMITTEE"S PREVIOUS OPINIONS
Opinion of 10 February 1993
Proposal for inclusion on the list of medicines refundable by National Health Insurance andon the list of medicines approved for hospital use and various public services in all the
therapeutic indications indicated in the Marketing Authorisation.Opinion of 4 December 1996 - Reassessment
Reassessment of actual benefit:
The treatments conventionally used in menopausal disorders are hormone replacement treatments for the menopause. The therapeutic use of ABUFENE is therefore limited.Opinion of the Committee of 19 January 2000
The Committee is awaiting the reassessment of the actual benefit of proprietary medicinal products in this class. Proposal for inclusion on the list of medicines refundable by National Health InsuranceOpinion of 2 April 2003 - Reassessment
The actual benefit of ABUFENE is low.
Opinion of 25 September 2005
Actual benefit
Hot flushes are common in menopausal women and can also arise as complications of hormone-dependent cancers (of the breast, uterus and ovaries). This condition is not life-threatening, nor does it cause serious complications, or any disability, or a marked deterioration in quality of life. This proprietary medicinal product is a symptomatic therapy. The efficacy/adverse effects ratio for this proprietary medicinal product is low.Alternative medicinal products exist.
The actual benefit of ABUFENE is low.
4/54. UPDATING OF AVAILABLE DATA SINCE THE PREVIOUS OPINION
A placebo-controlled study published in 1991
1 was not taken into consideration because of
methodological shortcomings (in particular: 44% of the female patients taking part were not menopausal, no description of the statistical tests used was provided). The pharmaceutical company has not provided any new data showing the efficacy ofABUFENE compared to the effect of a placebo.
5. DATA ON THE USE OF THE MEDICINE
According to IMS data (moving annual total November 2010), 377,000 prescriptions were issued for ABUFENE 400 mg. ABUFENE was prescribed mainly for menopausal and perimenopausal disorders (85.7%).6. TRANSPARENCY COMMITTEE CONCLUSIONS
6.1. Actual benefit
The vasomotor symptoms of the menopause can impair quality of life. This proprietary medicinal product is a symptomatic therapy. The data available are insufficient to distinguish between ABUFENE and a placebo. The efficacy/adverse effects ratio for this proprietary medicinal product is low. In the light of the data available, this proprietary medicinal product is not expected to have any impact on menopausal disorders and the quality of life of patients undergoing treatment compared to the alternatives available. Consequently, ABUFENE is not expected to have an impact on public health. ABUFENE has no role in the treatment strategy of menopausal hot flushes. There are treatment alternatives (hormone replacement treatments for the menopause, in accordance with the precautions for use, contraindications and Afssaps guidelines). In the light of this information, the Transparency Committee is of the opinion that the actual benefit of this proprietary medicinal product, which does not seem to be any more effectivethan a placebo, is insufficient to justify inclusion on the list of medicines refundable by
National Health Insurance.
1 Roueche J.C. et al. ABUFENE 400 mg et bouffées de chaleur. Etude en double aveugle versus
placebo. [ABUFENE 400 mg and hot flushes. Double-blind placebo-controlled study.] La revue du praticien - médecine générale. 1991 ; 5 : 2385-88 5/56.2. Therapeutic use
6.2.1 Therapeutic strategy
HTM is still indicated for menopausal women suffering from functional disorders that are associated with the menopause and that affect their quality of life. It must be prescribed at the lowest effective dose, for the shortest possible period, in accordance with the precautionsfor use and contraindications, after giving the patient clear information as to the risks.
Afssaps reminds physicians that all women undergoing HTM must have their treatment reviewed on a regular basis at least once a year 2.6.2.2 Therapeutic use of the proprietary medicinal product
As the available data is insufficient to distinguish between the proprietary medicinal product and a placebo in terms of efficacy, ABUFENE has no role in the treatment strategy of menopausal hot flushes.6.3. Transparency Committee recommendations
The Transparency Committee does not recommend continued inclusion on the list of medicines refundable by National Health Insurance in the indication and at the dosage in theMarketing Authorisation.
2 Afssaps - Traitement hormonal de la ménopause(THM) - Point d"information [Hormonal treatment of
the menopause (HTM) - update] - February 2008.quotesdbs_dbs47.pdfusesText_47[PDF] ac courant
[PDF] ac creteil disponibilité
[PDF] ac creteil imagin
[PDF] ac creteil iprof
[PDF] ac creteil resultat bac
[PDF] ac creteil webmail
[PDF] ac electricité
[PDF] ac martinique resultat brevet
[PDF] ac nantes imap
[PDF] ac nantes mail education
[PDF] ac nice esterel
[PDF] ac nice planete
[PDF] ac nice resultat
[PDF] ac nice svt